Canada - English - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 60mg - cabozantinib (cabozantinib malate) 60mg - antineoplastic agents

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4.2).paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.2).

Canada - English - Health Canada

merck canada inc - flutamide - tablet - 250mg - flutamide 250mg - antineoplastic agents

Canada - English - Health Canada

teva canada limited - flutamide - tablet - 250mg - flutamide 250mg - antineoplastic agents

Canada - English - Health Canada

pharmascience inc - flutamide - tablet - 250mg - flutamide 250mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

a-s medication solutions - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - goserelin 3.6 mg - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)]. zoladex is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see dosage and administration (2.3) and clinical studies (14.3)]. zoladex is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see dosage and administration (2.4) and cl

United States - English - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - goserelin 3.6 mg - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)]. zoladex is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see dosage and administration (2.3) and clinical studies (14.3)]. zoladex is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see dosage and administration (2.4) and cl

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - temsirolimus -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - axitinib 1mg;   - film coated tablet - 1 mg - active: axitinib 1mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry red 32k15441 - treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - axitinib 5mg;   - film coated tablet - 5 mg - active: axitinib 5mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry red 32k15441 - treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.